Invicta Diagnostic reports FY26 net profit of ₹48.73 Cr
Invicta Diagnostic Limited reported a consolidated net profit of ₹48.73 Cr for FY26, with total income rising to ₹330.42 Cr. EBITDA increased to ₹104.50 Cr, with a margin of 31.63%. The company invested ₹129.61 Cr in fixed assets and expanded its operations through new centres and acquisitions.
*this image is generated using AI for illustrative purposes only.
Invicta Diagnostic Limited reported a consolidated net profit of ₹48.73 Cr for the financial year ended March 31, 2026, compared to ₹49.30 Cr in the previous year. Total income for the period rose to ₹330.42 Cr from ₹301.81 Cr in FY25. The Board of Directors approved the audited standalone and consolidated financial results on May 18, 2026, in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The auditors, Kanak Rathod & Co., issued an unmodified opinion on the financial statements.
Financial Performance
The company achieved a consolidated EBITDA of ₹104.50 Cr for FY26, up from ₹92.90 Cr in the previous year. The EBITDA margin improved to 31.63% from 30.78%. For the second half of FY26, total income was recorded at ₹159.62 Cr with a net profit of ₹7.89 Cr. The EBITDA for H2 FY26 stood at ₹35.50 Cr, resulting in a margin of 22.24%.
| Metric | H2 FY26 | FY26 |
|---|---|---|
| Total Income | ₹ 159.62 Cr | ₹ 330.42 Cr |
| EBITDA | ₹ 35.50 Cr | ₹ 104.50 Cr |
| EBITDA Margin | 22.24% | 31.63% |
| Net Profit | ₹ 7.89 Cr | ₹ 48.73 Cr |
| Net Profit Margin | 4.94% | 14.74% |
| EPS | ₹ 0.79 | ₹ 4.90 |
During FY26, the company invested ₹129.61 Cr towards the purchase of fixed assets to support its long-term growth strategy. Depreciation expense increased by approximately 31% to ₹32.47 Cr in FY26 from ₹24.91 Cr in FY25.
Strategic Expansion
The company undertook several strategic initiatives during the period, including a joint venture entry into the Pune market. Invicta Diagnostic holds a 52% stake in the venture, which plans to establish diagnostic centres offering MRI, CT scan, and other services. The first centre has been secured at Market Yard, Pune.
Commercial operations commenced at the Dadar Centre on January 30, 2026, expanding the company's portfolio with PET-CT and CT scan facilities. The centre, located near Tata Memorial Hospital, was established with a project investment of approximately ₹55.00 Cr.
Additionally, the company received approval to acquire up to a 95% stake in Vinchurkar Diagnostics Private Limited, marking its entry into the Nashik market. The first phase of the acquisition was completed on May 8, 2026, securing a 51% controlling stake for a total consideration of ₹76.00 Cr.
Management Commentary
Sanket Vinod Jain, Chairman and Non-Executive Director, stated that FY26 was a landmark year with the company's NSE Emerge listing in December 2025. He highlighted the stable financial and operational performance, noting the maintenance of EBITDA margins in excess of 30%. The company remains focused on expanding its diagnostics network and driving sustainable growth in FY27.
Historical Stock Returns for Invicta Diagnostic
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.72% | -7.05% | -33.61% | -33.39% | -38.00% | -38.00% |
What is the expected timeline for the Vinchurkar Diagnostics acquisition to reach the full 95% stake, and how will the remaining consideration be funded?
How will the significant capital expenditure of ₹129.61 Cr impact cash flows and profitability in FY27 as the new centres in Pune, Dadar, and Nashik ramp up operations?
What strategies will management employ to address the sharp decline in profitability during H2 FY26 compared to the first half?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
